797 related articles for article (PubMed ID: 24834811)
1. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
[TBL] [Abstract][Full Text] [Related]
4. Subgroup Analysis for Chinese Patients Included in the INPULSIS
Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
[TBL] [Abstract][Full Text] [Related]
5. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA
Respir Res; 2015 Sep; 16():116. PubMed ID: 26400368
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Costabel U; Inoue Y; Richeldi L; Collard HR; Tschoepe I; Stowasser S; Azuma A
Am J Respir Crit Care Med; 2016 Jan; 193(2):178-85. PubMed ID: 26393389
[TBL] [Abstract][Full Text] [Related]
12. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
15. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Kolb M; Richeldi L; Behr J; Maher TM; Tang W; Stowasser S; Hallmann C; du Bois RM
Thorax; 2017 Apr; 72(4):340-346. PubMed ID: 27672117
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Kolb M; Raghu G; Wells AU; Behr J; Richeldi L; Schinzel B; Quaresma M; Stowasser S; Martinez FJ;
N Engl J Med; 2018 Nov; 379(18):1722-1731. PubMed ID: 30220235
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Mazzei ME; Richeldi L; Collard HR
Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
